Molly S Moye1, Sallyann M C King2, Zakiya P Rice3, Laura K DeLong3, Anne M Seidler4, Emir Veledar5, Clara Curiel-Lewandrowski6, Suephy C Chen7. 1. Department of Dermatology, Emory University, Atlanta, Georgia2currently with the Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City. 2. Department of Dermatology, Emory University, Atlanta, Georgia3currently with the Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Department of Dermatology, Emory University, Atlanta, Georgia. 4. Department of Dermatology, Emory University, Atlanta, Georgia4currently with Kaiser Permanente, Oakland, California. 5. Department of Dermatology, Emory University, Atlanta, Georgia5Center for Research and Grants, Baptist Health South Florida, Coral Gables. 6. Skin Cancer Institute/Arizona Cancer Center, Division of Dermatology, University of Arizona, Tucson. 7. Department of Dermatology, Emory University, Atlanta, Georgia7Division of Dermatology, Atlanta Veterans Affairs Medical Center, Decatur, Georgia.
Abstract
IMPORTANCE: Cancer worry about developing melanoma in at-risk patients may affect one's quality of life and adherence to screening. Little is known about melanoma-related worry in patients with atypical mole syndrome (AMS). OBJECTIVES: To quantify levels and elucidate predictors of worry related to developing melanoma in patients with AMS and to determine whether total-body digital photography (TBDP) in pigmented lesion clinics (PLCs) reduces worry. DESIGN, SETTING, AND PARTICIPANTS: In this pretest-posttest study, patients with AMS from PLCs at 2 academic medical centers were recruited from June 1, 2005, through October 31, 2008, to answer questions about cancer worry before and after undergoing TBDP. Questionnaires used included the new melanoma and recurrent melanoma Revised Impact of Event Scale (RIES), the Melanoma Worry Scale (MWS), the Hospital Anxiety and Depression Scale, and the Life Orientation Test. INTERVENTIONS: All patients underwent TBDP. MAIN OUTCOMES AND MEASURES: Changes in the MWS and new melanoma RIES scores. RESULTS: A total of 138 patients completed baseline questionnaires; 108 patients (78.3%) completed questionnaires after TBDP. Baseline levels of worry were low and reduced further after TBDP. In patients with a personal history of melanoma, worry was reduced on all scales. In patients without a personal history of melanoma, only the new melanoma RIES score was significantly decreased. Predictors of baseline MWS scores include female sex, personal history of melanoma, and higher Hospital Anxiety and Depression Scale scores, adjusted for demographics, family history of melanoma, and Life Orientation Test scores. Adjusted predictors of the baseline new melanoma RIES score were similar but also included lower educational level and did not include sex. CONCLUSIONS AND RELEVANCE: Patients with AMS have low levels of melanoma-related worry, which is similar to data from other populations at high risk of cancers. We found that TBDP is a clinically useful tool that can be used in PLCs to help decrease worry about developing melanoma in at-risk patients.
IMPORTANCE: Cancer worry about developing melanoma in at-risk patients may affect one's quality of life and adherence to screening. Little is known about melanoma-related worry in patients with atypical mole syndrome (AMS). OBJECTIVES: To quantify levels and elucidate predictors of worry related to developing melanoma in patients with AMS and to determine whether total-body digital photography (TBDP) in pigmented lesion clinics (PLCs) reduces worry. DESIGN, SETTING, AND PARTICIPANTS: In this pretest-posttest study, patients with AMS from PLCs at 2 academic medical centers were recruited from June 1, 2005, through October 31, 2008, to answer questions about cancer worry before and after undergoing TBDP. Questionnaires used included the new melanoma and recurrent melanoma Revised Impact of Event Scale (RIES), the Melanoma Worry Scale (MWS), the Hospital Anxiety and Depression Scale, and the Life Orientation Test. INTERVENTIONS: All patients underwent TBDP. MAIN OUTCOMES AND MEASURES: Changes in the MWS and new melanoma RIES scores. RESULTS: A total of 138 patients completed baseline questionnaires; 108 patients (78.3%) completed questionnaires after TBDP. Baseline levels of worry were low and reduced further after TBDP. In patients with a personal history of melanoma, worry was reduced on all scales. In patients without a personal history of melanoma, only the new melanoma RIES score was significantly decreased. Predictors of baseline MWS scores include female sex, personal history of melanoma, and higher Hospital Anxiety and Depression Scale scores, adjusted for demographics, family history of melanoma, and Life Orientation Test scores. Adjusted predictors of the baseline new melanoma RIES score were similar but also included lower educational level and did not include sex. CONCLUSIONS AND RELEVANCE: Patients with AMS have low levels of melanoma-related worry, which is similar to data from other populations at high risk of cancers. We found that TBDP is a clinically useful tool that can be used in PLCs to help decrease worry about developing melanoma in at-risk patients.
Authors: Katie Mills; Jon Emery; Rebecca Lantaff; Michael Radford; Merel Pannebakker; Per Hall; Nigel Burrows; Kate Williams; Catherine L Saunders; Peter Murchie; Fiona M Walter Journal: BMJ Open Date: 2017-11-28 Impact factor: 2.692
Authors: Jenna E Rayner; Antonia M Laino; Kaitlin L Nufer; Laura Adams; Anthony P Raphael; Scott W Menzies; H Peter Soyer Journal: Front Med (Lausanne) Date: 2018-05-23
Authors: P Murchie; J Masthoff; F M Walter; K Rahman; J L Allan; N Burrows; C Proby; A J Lee; M Johnston; A Durrani; I Depasquale; B Brant; A Neilson; F Meredith; S Treweek; S Hall; A McDonald Journal: Trials Date: 2019-06-03 Impact factor: 2.279
Authors: Fiona M Walter; Merel M Pannebakker; Matthew E Barclay; Katie Mills; Catherine L Saunders; Peter Murchie; Pippa Corrie; Per Hall; Nigel Burrows; Jon D Emery Journal: JAMA Netw Open Date: 2020-02-05